Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Open-label, Long-term Extension Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT06723106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06723106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Open-label, Long-term Extension Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW-LTE Trial)
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
December 9, 2024
Completion date
February 28, 2028
Enrollment
144 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome (aps), behçet's syndrome (bs), bullous pemphigoid (bp), dermatomyositis (dm), immune thrombocytopenia (itp), immune-mediated necrotizing myopathy (imnm)